Newsletter | October 3, 2023

10.03.23 -- Targeting RNA With Small Molecules


Webinar: Meeting The Challenge Of Rising API Complexity — AI And Lonza IP-Enabled Route Design Technology

Join us to learn how our subject matter experts, leveraging award-winning AI- and Lonza IP-enabled synthesis design technology and proprietary supply chain analytics, are helping companies accelerate IND readiness, increase supply chain security, and cultivate collaborative partnerships. Click here to learn more.


Targeting RNA With Small Molecules

Beyond mRNA's dogmatic role as the intermediate in gene expression, noncoding RNA play essential roles in transcription regulation, maturation, and translation. This article explores the potential of RNA as a clinically validated avenue for drug development, methods for design and discovery, and implications for the future of medicine.


Fixed-Dose Combination Drugs

A company was seeking a CDMO partner with the expertise and technological capabilities to combine three drug substances into a fixed-dose combination product suitable for adult and pediatric dosing.

Ultra-High Potency Development And Manufacture

A biotech with limited experience in the development and manufacture of high potency compounds sought to develop a process for producing a highly potent API used to treat an unmet oncology need.

Developing Biosimilars: Challenges And Solutions

Biophysical characterization requires technologies that often require expensive reagents, large quantities of samples, and experimental conditions optimization. Simplified analytical workflows can help.

Increase Spray Drying Throughput For Brick Dust Compounds

We discuss three enabling technologies designed to improve drug solubility in organic solvents for spray drying and define the advantages and risks of each technology.

Local Delivery For Treatment Of Lung Cancer

Explore two case studies where lung cancer therapies were delivered to the lung by dry powder inhaler in a rat model and evaluated for efficacy, confirming local delivery is a promising route to treat lung cancer.


Quantzig Revolutionizes Drug Discovery For Prominent US Pharmaceutical Leader

Drug Discovery On An Unprecedented Scale

Novo Nordisk & Evotec Collaborate To Launch LAB eN²

Pierre Fabre Laboratories & Vernalis Announce A Long-Term Partnership

Chrysalis Receives FDA Approval To Initiate Clinical Trials With Chrysalin (TP508)

ABM Therapeutics' ABM-1310 Granted Fast Track Designation By The FDA

FDA Accepts Defender Pharmaceuticals’ NDA For Intranasal Scopolamine Gel

Phathom Pharmaceuticals Announces Vonoprazan NDA Submission

Twist Bioscience & IMIDomics Collab To Discover Antibodies For Applications In IMIDs

Viatris & Ocuphire Pharma Announce FDA Approval Of RYZUMVl

Ono Enters Into A Drug Discovery Collaboration Agreement With Adimab


Surfactant Analysis Services

Addressing Some Of The Most Common Surface Plasmon Resonance Questions


Have you heard of Life Science Leader?
Check it out today for access to candid interviews with top-tier executives on how they do business.